Prognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Dec 17

PMID 39685780

Authors

Oliver Illini

Michal Benej

Anna Sophie Lang-Stoberl

Hannah Fabikan

Luka Brcic

Florian Sucher

Dagmar Krenbek

Tibor Krajc

Christoph Weinlinger

Maximilian J Hochmair

Arschang Valipour

Thomas Klikovits

Stefan Watzka

Affiliations

Soon will be listed here.

Abstract

: Pleural mesothelioma (PM) is a rare type of cancer with poor prognosis. Prognostic and predictive biomarkers could improve treatment strategies in these patients. Programmed death ligand 1 (PD-L1), integrin-linked kinase (ILK) and breast cancer gene 1-associated protein (BAP-1) have been proposed to predict outcomes in PM, but existing data are limited and controversial. This single-center, retrospective study analyzed data on expression patterns and the prognostic role of PD-L1, ILK and BAP-1 in consecutive patients diagnosed with PM. Of all patients (n = 52) included, more than half showed a positive PD-L1 expression (52% TPS ≥ 1%, 65% CPS ≥ 1), 69% showed a BAP-1 loss and 80% an ILK ≥ 50%. Positive PD-L1 expression was more frequent in the non-epithelioid subtype ( = 0.045). ILK intensity ( = 0.032) and positive PD-L1 ( = 0.034) were associated with more advanced tumor stages. The median overall survival (OS) was 16.9 (95% CI 13.1-25.2) months. Multimodality therapy (MMT) including surgery and early stage were independent prognostic factors for longer OS (MMT: HR 0.347, 95% CI 0.13-0.90, = 0.029; advanced stage: HR 4.989; 95% CI 1.64-15.13, = 0.005). Patients with an expression of PD-L1 TPS ≥ 1% or BAP-1 positivity showed numerically worse survival with a median OS of 15.3 (11.5; 24.4) vs. 20.0 (11.2; 34.9) and 11.3 (5.6; 31.0) vs. 20.0 (15.2; 28.1) months, respectively. Furthermore, PD-L1 was associated with worse survival in patients receiving MMT (PD-L1 TPS ≥ 1%: 15.8 (12.1-25.4) vs. 31.3 (17.4-95.4) = 0.053). ILK expression ≥50% did not influence survival. The combinations of CPS ≥ 1% with BAP-1 positivity or ILK expression ≥50% were associated with worse survival ( = 0.045, = 0.019). In this real-world analysis, expressions of PD-L1 and BAP-1 were associated with worse survival in patients with PM. ILK showed no prognostic value. Further studies with larger cohorts are needed to identify prognostic and predictive biomarkers facilitating optimized individual treatment decision in this rare type of cancer.

References

Huang J, Chan S, Pang W, Chow S, Lok V, Zhang L . Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study. J Thorac Oncol. 2023; 18(6):792-802. DOI: 10.1016/j.jtho.2023.01.095. View

Sauter J, Dacic S, Galateau-Salle F, Attanoos R, Butnor K, Churg A . The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. J Thorac Oncol. 2022; 17(5):608-622. DOI: 10.1016/j.jtho.2021.12.014. View

De Marchi P, Leal L, da Silva V, da Silva E, Cordeiro de Lima V, Reis R . PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC). J Clin Pathol. 2021; 74(11):735-740. DOI: 10.1136/jclinpath-2020-206832. View

Curran D, Sahmoud T, Therasse P, Van Meerbeeck J, Postmus P, Giaccone G . Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998; 16(1):145-52. DOI: 10.1200/JCO.1998.16.1.145. View

Ghafoor A, Hassan R . Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy. J Thorac Oncol. 2022; 17(7):862-864. DOI: 10.1016/j.jtho.2022.05.005. View

Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson A, Nowak A . Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 33(2):129-142. DOI: 10.1016/j.annonc.2021.11.005. View

Rusch V, Giroux D, Kennedy C, Ruffini E, Cangir A, Rice D . Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012; 7(11):1631-9. DOI: 10.1097/JTO.0b013e31826915f1. View

Louw A, Panou V, Szejniuk W, Meristoudis C, Chai S, van Vliet C . BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study. J Thorac Oncol. 2022; 17(7):921-930. DOI: 10.1016/j.jtho.2022.04.008. View

Lim E, Waller D, Lau K, Steele J, Pope A, Ali C . Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024; 12(6):457-466. PMC: 11136673. DOI: 10.1016/S2213-2600(24)00119-X. View

10.

Nguyen B, Montgomery R, Fadia M, Wang J, Ali S . PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma. Asia Pac J Clin Oncol. 2017; 14(1):69-73. DOI: 10.1111/ajco.12788. View

11.

Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272):375-386. DOI: 10.1016/S0140-6736(20)32714-8. View

12.

Klikovits T, Stockhammer P, Laszlo V, Dong Y, Hoda M, Ghanim B . Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Sci Rep. 2017; 7(1):16456. PMC: 5705645. DOI: 10.1038/s41598-017-16551-7. View

13.

Tamura T, Ohira M, Tanaka H, Muguruma K, Toyokawa T, Kubo N . Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. Anticancer Res. 2015; 35(10):5369-76. View

14.

Betti M, Aspesi A, Ferrante D, Sculco M, Righi L, Mirabelli D . Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes. Genes Chromosomes Cancer. 2018; 57(11):573-583. DOI: 10.1002/gcc.22670. View

15.

Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C . Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev. 1997; 6(2):162-6. View

16.

Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M . PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655):495-499. PMC: 5931375. DOI: 10.1038/nature22396. View

17.

Remon J, Passiglia F, Ahn M, Barlesi F, Forde P, Garon E . Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. J Thorac Oncol. 2020; 15(6):914-947. DOI: 10.1016/j.jtho.2020.03.006. View

18.

Hajj G, Cavarson C, Pinto C, Venturi G, Navarro J, Cordeiro de Lima V . Malignant pleural mesothelioma: an update. J Bras Pneumol. 2021; 47(6):e20210129. PMC: 8836658. DOI: 10.36416/1806-3756/e20210129. View

19.

Brosseau S, Danel C, Scherpereel A, Mazieres J, Lantuejoul S, Margery J . Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. Clin Lung Cancer. 2019; 20(5):e564-e575. DOI: 10.1016/j.cllc.2019.04.010. View

20.

Cedres S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A . Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One. 2015; 10(3):e0121071. PMC: 4361537. DOI: 10.1371/journal.pone.0121071. View